PTC THERAPEUTICS, INC. — Director's Dealing 2020

Oct 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2020-10-05

Reporting Person: Utter Christine Marie (SVP, Finance & CAO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-05	Common Stock	M	787	$11.23	Acquired	10349	Direct
2020-10-05	Common Stock	S	787	$48.68	Disposed	9562	Direct
2020-10-06	Common Stock	M	2500	$18.01	Acquired	12062	Direct
2020-10-06	Common Stock	S	2500	$50.083	Disposed	9562	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-05	Stock Option (Right To Buy)	$11.23	M	787	Disposed	2027-01-02	Common Stock (787.0)	Direct
2020-10-06	Stock Option (Right to Buy)	$18.01	M	2500	Disposed	2028-01-02	Common Stock (2500)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right To Buy)	$490.8	2021-04-27	Common Stock (74.0)	74	Direct
Stock Option (Right To Buy)	$218.4	2022-01-10	Common Stock (21.0)	21	Direct
Stock Option (Right To Buy)	$40.45	2024-09-23	Common Stock (4688.0)	4688	Direct
Stock Option (Right To Buy)	$51.0	2025-01-02	Common Stock (17800.0)	17800	Direct
Stock Option (Right To Buy)	$30.86	2026-01-03	Common Stock (10310.0)	10310	Direct
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (42500.0)	42500	Direct
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (10100.0)	10100	Direct
Stock Option (Right To Buy)	$51.16	2030-01-28	Common Stock (23800.0)	23800	Direct

Footnotes

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 1, 2019.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.36 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

F4: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

F5: Currently exercisable.

F6: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.

F7: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.

F8: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.